No Data
No Data
Express News | HC Wainwright & Co. Reiterates Neutral on Durect
Durect Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 — HC Wainwright & Co. Reiterates → Neutral 04/01/2024 449.39% Oppenheimer → $5 Reiterates Outp
Durect | 10-Q: Quarterly report
Express News | DURECT Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q1 Revenue Results
Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says
Durect (DRRX) is not yet an earnings story but recent feedback from the US Food and Drug Administration is encouraging over its support for the advancement of larsucosterol into a single late-stage tr
Cutera, Inotiv, Treace Medical Concepts Among Healthcare Movers
loading...
loading...
No Data